Biophytis Finalizes €2.6 Million Private Placement

Biophytis SA has confirmed the settlement and delivery of its €2.6 million private placement. This includes the issuance of over 4 million new shares, each paired with a warrant, and nearly 5.7 million prepaid subscription warrants. These securities have been admitted for trading on Euronext Growth Paris.

The issue price results in a discount of 24.1% relative to the 5-day volume-weighted average price. Maxim Group LLC served as the lead placement agent. The shareholding structure has been updated, correcting earlier errors in reported voting rights.

This private placement supports Biophytis' focus on treatments for age-related diseases, including muscle and metabolic disorders. The company's shares are publicly traded under ISIN code FR001400OLP5.